Invesco
CMPX icon

Invesco’s Compass Therapeutics CMPX Stock Holding History

Invesco’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153K Sell
69,818
-31,389
-31% -$92.7K ﹤0.01% 3661
2026
Q1 		$535K Buy
101,207
+37,306
+58% +$215K ﹤0.01% 3138
2025
Q4 		$343K Buy
63,901
+3,245
+5% +$15K ﹤0.01% 3334
2025
Q3 		$212K Buy
60,656
+1,921
+3% +$6.07K ﹤0.01% 3548
2025
Q2 		$153K Buy
58,735
+21,578
+58% +$44.5K ﹤0.01% 3579
2025
Q1 		$70.6K Sell
37,157
-2,326
-6% -$6.18K ﹤0.01% 3672
2024
Q4 		$57.3K Buy
39,483
+4,018
+11% +$6.67K ﹤0.01% 3679
2024
Q3 		$65.3K Sell
35,465
-1,937
-5% -$2.41K ﹤0.01% 3659
2024
Q2 		$37.4K Sell
37,402
-4,361
-10% -$6.37K ﹤0.01% 3845
2024
Q1 		$82.7K Sell
41,763
-1,427
-3% -$2.47K ﹤0.01% 3762
2023
Q4 		$67.4K Sell
43,190
-22,906
-35% -$39.6K ﹤0.01% 3730
2023
Q3 		$130K Buy
66,096
+27,452
+71% +$67.9K ﹤0.01% 3685
2023
Q2 		$123K Buy
+38,644
New +$121K ﹤0.01% 3691

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Invesco's CMPX Position: Q2 2026 in Review

Invesco reduced its Compass Therapeutics (CMPX) stake by 31% in Q2 2026, selling an estimated $92.7K and leaving 69,818 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #3661.

Invesco first reported a position in CMPX in Q2 2023 and has held it in 13 quarters since. The position peaked at $535K in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Invesco held 69,818 shares of Compass Therapeutics worth $153K as of Q2 2026.
  • Invesco sold 31,389 Compass Therapeutics shares in Q2 2026, an estimated $92.7K.
  • Compass Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3661 holding.
  • Invesco first reported a position in Compass Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • Invesco's Compass Therapeutics position peaked at $535K in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.